NASDAQ:COLL

Collegium Pharmaceutical Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy COLL

*Your capital is at risk

$31.06

+0.580 (+1.90%)

At Close: Jun 03, 2026

Collegium Pharmaceutical Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -64.76. In total, the insiders bought 860.21K and sold 468.05K COLL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-64.76
● Buy	860.21K shares
● Sell	468.05K shares
62% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Mar 03, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -64.76. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 10, 2026 Buy	Common Stock A-Award	Karnani Vikram President And CEO	CEO / President	32 531 Value: $1.52M
Feb 10, 2026 Buy	Common Stock A-Award	Dieter David EVP & General Counsel	Officer	22 194 Value: $1.04M
Feb 10, 2026 Sell	Common Stock F-InKind	Dieter David EVP & General Counsel	Officer	2 781 Value: $130.0K
Feb 10, 2026 Buy	Common Stock A-Award	Dieter David EVP & General Counsel	Officer	9 005 Value: $421.0K
Feb 10, 2026 Buy	Common Stock A-Award	Karnani Vikram President And CEO	CEO / President	79 264 Value: $3.71M
Feb 10, 2026 Buy	Common Stock A-Award	Smith Thomas B EVP And Chief Medical Officer	Officer	22 774 Value: $1.06M
Feb 10, 2026 Sell	Common Stock F-InKind	Smith Thomas B EVP And Chief Medical Officer	Officer	5 897 Value: $275.7K
Feb 10, 2026 Sell	Common Stock F-InKind	Smith Thomas B EVP And Chief Medical Officer	Officer	11 538 Value: $539.4K
Feb 10, 2026 Buy	Common Stock A-Award	Smith Thomas B EVP And Chief Medical Officer	Officer	14 268 Value: $667.0K
Feb 10, 2026 Buy	Common Stock A-Award	Dreyer Scott EVP & Chief Commercial Officer	Officer	30 702 Value: $1.44M
Feb 10, 2026 Sell	Common Stock F-InKind	Dreyer Scott EVP & Chief Commercial Officer	Officer	9 977 Value: $466.4K
Feb 10, 2026 Buy	Common Stock A-Award	Dreyer Scott EVP & Chief Commercial Officer	Officer	19 023 Value: $889.3K
Feb 10, 2026 Sell	Common Stock F-InKind	Dreyer Scott EVP & Chief Commercial Officer	Officer	21 615 Value: $1.01M
Dec 08, 2025 Buy	Common Stock M-Exempt	Dreyer Scott EVP & Chief Commercial Officer	Officer	17 600 Value: $279.8K
Dec 08, 2025 Sell	Common Stock S-Sale	Dreyer Scott EVP & Chief Commercial Officer	Officer	11 125 Value: $532.8K
Dec 08, 2025 Sell	Common Stock S-Sale	Dreyer Scott EVP & Chief Commercial Officer	Officer	6 475 Value: $315.1K
Dec 08, 2025 Buy	Stock Option (Right to Purchase) M-Exempt	Dreyer Scott EVP & Chief Commercial Officer	Officer	17 600 Value: $279.8K
Dec 05, 2025 Sell	Common Stock S-Sale	Balice-gordon Rita J. Director	Director	3 650 Value: $171.7K
Nov 12, 2025 Sell	Common Stock F-InKind	Karnani Vikram President And CEO	CEO / President	8 983 Value: $425.3K
Nov 12, 2025 Buy	Common Stock M-Exempt	Fallon John A. Director	Director	19 853 Value: $185.2K
Nov 12, 2025 Buy	Common Stock M-Exempt	Fallon John A. Director	Director	15 000 Value: $247.4K
Nov 12, 2025 Sell	Common Stock S-Sale	Fallon John A. Director	Director	34 853 Value: $1.65M
Nov 12, 2025 Buy	Stock Option (Right to Purchase) M-Exempt	Fallon John A. Director	Director	15 000 Value: $247.4K
Nov 12, 2025 Buy	Stock Option (Right to Purchase) M-Exempt	Fallon John A. Director	Director	19 853 Value: $185.2K
Nov 06, 2025 Sell	Common Stock S-Sale	Tupper Colleen EVP & Chief Financial Officer	C-Suite Officer	25 142 Value: $1.02M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT COLLEGIUM PHARMACEUTICAL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatm...

Read Full Profile Here